Known targets — ChEMBL curated mechanism
GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHMGCRMMP1MMP13MMP7MMP8PTGS1PTGS2ileSpolrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Levocarnitine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A16 | Q86VW1 | 1/20 | 0.83 |
| ▸ | CPT2 | P23786 | 3/20 | 0.53 |
| ▸ | CPT1A | P50416 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | HRH1 | P35367 | 1/20 | 0.47 |
| ▸ | CRAT | P43155 | 1/20 | 0.47 |
| ▸ | SLC25A20 | O43772 | 3/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | CPT1B | Q92523 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Carnitine SCHEMBL3897376 | 1.00 | SLC22A16 (0.83) | SLC22A16CPT2CPT1AMEN1KMT2A | |
| Carnitine SCHEMBL1719821 | 0.94 | SLC22A16 (0.95) | SLC22A16CPT2CPT1AMEN1KMT2A | |
| Carnitine SCHEMBL17629811 | 0.91 | SLC22A16 (1.00) | SLC22A16CPT2CPT1AMEN1KMT2A | |
| Carnitine SCHEMBL1813524 | 0.91 | SLC22A16 (1.00) | SLC22A16CPT2CPT1AMEN1KMT2A | |
| Levocarnitine SCHEMBL4593172 | 0.91 | SLC22A16 (1.00) | SLC22A16CPT2CPT1AMEN1KMT2A | |
| D-Carnitine SCHEMBL94286 | 0.91 | SLC22A16 (1.00) | SLC22A16CPT2CPT1AMEN1KMT2A | |
| Carnitine SCHEMBL21971 | 0.91 | SLC22A16 (1.00) | SLC22A16CPT2CPT1AMEN1KMT2A | |
| Carnitine SCHEMBL3902633 | 0.91 | SLC22A16 (1.00) | SLC22A16CPT2CPT1AMEN1KMT2A | |
| Levocarnitine SCHEMBL21970 | 0.91 | SLC22A16 (1.00) | SLC22A16CPT2CPT1AMEN1KMT2A | |
| Levocarnitine SCHEMBL3005246 | 0.90 | SLC22A16 (0.80) | SLC22A16CPT2CPT1AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7572832-B2 | Non-hygroscopic L-carnitine salts | BIOLINK LIFE SCIENCES, INC. (US) | 2009-08-11 | — | — | US | disclosed |
| US-20080234371-A1 | Non-hygroscopic L-carnitine salts | BIOLINK LIFE SCIENCES, INC. | 2008-09-25 | — | — | US | disclosed |
| WO-2008115915-A2 | NON-HYGROSCOPIC L-CARNITINE SALTS | BIOLINK LIFE SCIENCES, INC. (US) | 2008-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234371-A1 | Non-hygroscopic L-carnitine salts | CRAT, SLC25A20, CPT1B | SLC22A16 75/4885CPT2 4/4885CPT1A 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.